GT Biopharma (GTBP)
NASDAQ:GTBP
Want to see GTBP full AI Analyst Report?
GTBP Stock Chart & Stats
$0.73
-$0.23(-8.01%)
At close: 4:00 PM EST
$0.73
-$0.23(-8.01%)
Day’s Range― - ―
52-Week Range$0.26 - $3.85
Previous CloseN/A
Volume15.05K
Average Volume (3M)1.63M
Market Cap
$16.85M
Enterprise Value-$3.84M
Total Cash (Recent Filing)$8.92M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Aug 12, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.46
Shares Outstanding36,062,904
10 Day Avg. Volume1,818,785
30 Day Avg. Volume1,629,462
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.75
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market Cap-0.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial Collaboration (GTB-5550)A University of Minnesota-sponsored phase 1a/1b program materially advances GTB-5550 toward human data while shifting IND sponsorship and operational burden to an academic partner. This reduces execution risk, validates the TriKE approach if data are positive, and provides a structured, funded pathway for early clinical proof-of-concept.
Very Low LeverageHaving no reported debt in 2025 and TTM lowers immediate solvency risk and interest obligations, giving management financial flexibility. This durable balance-sheet characteristic reduces bankruptcy risk and allows the company to prioritize R&D and strategic partnerships without near-term debt maturities pressuring cash flow.
NK Cell–engaging Immuno-oncology PlatformA focused platform in NK cell–engaging biologics positions the company within a growing, structural immuno-oncology trend. As a specialist in engineered biologics and TriKE candidates targeting tumor antigens, the company can leverage platform know-how across programs, supporting durable differentiation if clinical translation succeeds.
Bears Say
Pre-revenue With Persistent LossesBeing pre-revenue with recurring multi-year net losses limits internal funding capacity and creates dependence on external capital markets. Over the medium term this elevates dilution and execution risk, since sustained development and commercialization require substantial cash before any product revenue can offset operating losses.
Consistent Negative Operating Cash FlowPersistent negative operating cash flow and free cash flow in every period establishes a structural cash-burn profile. This creates a ticking financing need tied to trial timelines and R&D spend, constraining strategic optionality and raising the probability of future equity or dilutive financing that can affect long-term capital structure.
Volatile Shareholders' EquityWide swings in shareholders' equity reflect prior losses and capital raises, signaling a fragile equity base. This volatility reduces the financial buffer to absorb clinical setbacks or prolonged development, increasing reliance on new financing rounds and elevating long-term dilution and governance risk for existing shareholders.
GT Biopharma News
GTBP FAQ
What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest stock price was $0.26 and its highest was $3.85 in the past 12 months.
What is GT Biopharma’s market cap?
GT Biopharma’s market cap is $16.85M.
When is GT Biopharma’s upcoming earnings report date?
GT Biopharma’s upcoming earnings report date is Aug 12, 2026 which is in 70 days.
How were GT Biopharma’s earnings last quarter?
GT Biopharma released its earnings results on May 18, 2026. The company reported -$0.11 earnings per share for the quarter, the consensus estimate of -$0.11 by $0.
Is GT Biopharma overvalued?
According to Wall Street analysts GT Biopharma’s price is currently Overvalued.
Does GT Biopharma pay dividends?
GT Biopharma does not currently pay dividends.
What is GT Biopharma’s EPS estimate?
GT Biopharma’s EPS estimate is -0.08.
How many shares outstanding does GT Biopharma have?
GT Biopharma has 36,062,904 shares outstanding.
What happened to GT Biopharma’s price movement after its last earnings report?
GT Biopharma reported an EPS of -$0.11 in its last earnings report, expectations of -$0.11. Following the earnings report the stock price went down -7.379%.
Which hedge fund is a major shareholder of GT Biopharma?
Currently, no hedge funds are holding shares in GTBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GT Biopharma
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
Technical Analysis
Theriva Biologics
―
Revelation Biosciences
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Azitra Inc
―
Ownership Overview
2.37%
Insiders
1.33% Mutual Funds
0.67% Other Institutional Investors
94.37% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---